UNBX (Unity Biotechnology) Earnings Yield %: N/A% (As of Jul. 02, 2026)


What is Unity Biotechnology Earnings Yield %?

Unity Biotechnology UNBX Earnings Yield % is N/A% as of Jul. 02, 2026.

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2026-07-02), the stock price of Unity Biotechnology is $0.0561. Unity Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.62. Therefore, Unity Biotechnology's earnings yield of today is N/A%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Unity Biotechnology's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

Unity Biotechnology  (OTCPK:UNBX) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.

Unity Biotechnology Earnings Yield % Related Terms

Unity Biotechnology Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

Unity Biotechnology's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=-1.620/0.0561
=N/A %

Unity Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.620 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.

Frequently Asked Questions Learn more about Earnings Yield % →
What does a Earnings Yield % of N/A% mean?
Unity Biotechnology (UNBX) has a Earnings Yield % of N/A% as of Jul. 02, 2026. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on Unity Biotechnology and its competitors.
Is Unity Biotechnology's Earnings Yield % too high?
Unity Biotechnology's current Earnings Yield % is N/A%.
How does Unity Biotechnology's Earnings Yield % compare to ADTX and HEPA?
Unity Biotechnology's Earnings Yield % of N/A% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield % for a Biotechnology company?
A good Earnings Yield % depends on the Biotechnology industry context. However, Earnings Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield % mean?
A high Earnings Yield % can signal that a stock is expensive relative to its fundamentals. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on Unity Biotechnology and its competitors. Unity Biotechnology's current Earnings Yield % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unity Biotechnology stock overvalued right now?
Unity Biotechnology (UNBX) has a current Earnings Yield % of N/A%. The current Earnings Yield % is N/A%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield % calculated?
Earnings Yield % is calculated from a company's financial statements. For Unity Biotechnology (UNBX), the current Earnings Yield % is N/A% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unity Biotechnology Business Description

Address 285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.